TRACON Pharmaceuticals Announces Acceptance of the Envafolimab (KN035) NDA by the NMPA in China that was Submitted by its Corporate Partners Alphamab Oncology and 3D Medicines

Ads

You May Also Like

Novartis’ Xolair® recommended in new global chronic urticaria guideline

Xolair® (omalizumab), indicated as add-on therapy for the treatment of chronic spontaneous urticaria (CSU)[1], ...

Aptevo Therapeutics to Present at the 30th Annual ROTH Conference

SEATTLE, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company ...